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Abstract
Epidermal growth factor (EGF) is synthesized in the pancreas and diabetic animals have low levels of EGF. However, the role of EGF in
regulating the major function of the pancreas, insulin secretion, has not been studied. Here, we show that EGF rapidly increased insulin
secretion in mouse pancreatic islets, as well as in a pancreatic -cell line. These events were dependent on a Ca2 influx and phospho-
lipase D (PLD) activity, particularly PLD2, as determined using pharmacological blockers and molecular manipulations such as over-expres-
sion and siRNA of PLD isozymes. In addition, EGF also increased plasma insulin levels and mediated glucose lowering in normal and diabetic
mice. Here, for the first time, we provide evidence that EGF is a novel secretagogue that regulates plasma glucose levels and a candidate for
the development of therapeutics for diabetes.
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Introduction
The main function of pancreatic  cells is to synthesize and
secrete insulin at appropriate rates to limit blood glucose fluctua-
tions. Excessive secretion of insulin causes hypoglycemia, and
insufficient secretion leads to diabetes [1]. Therefore, it is not sur-
prising that insulin secretion is subject to very tight control to
ensure glucose homeostasis in the body. Insulin is stored in
secretory granules in pancreatic  cells and, upon stimulation with
secretagogues, is released by exocytosis [2]. The level of -cell
activity is determined by several different stimulators, including
glucose, amino acids, fatty acids, neurotransmitters and hor-
mones. In spite of intensive studies, the processes that are
involved in this stimulus–secretion coupling and that maintain
exquisite control of insulin release are still incompletely under-
stood [1, 3–5].
Epidermal growth factor (EGF) is an important growth factor
for the proliferation of different types of cells, especially fibrob-
lasts and epithelial cells [8]. EGF can also induce secretion
events, including acrosomal exocytosis and the secretion of
several hormones [9, 10]. Some members of the EGF family are
proposed to have a role in the development of the pancreas. EGF
and leukemia inhibitory factor (LIF) treatment in vitro generated
an insulin-producing -cell mass [11]. The epidermal growth
factor receptor (EGFR) is expressed throughout the human
foetal pancreas, and mice lacking EGFR show abnormal pancre-
atic islets [12]. EGF is also related to the insulin content and
regeneration of rat pancreatic  cells. [13–15]. EGF is also pro-
duced in the pancreas, and its circulating levels, along with
EGFR, are reduced in diabetic animals [6, 7, 16]. However, the
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role of EGF in glucose regulation through the modulation of
pancreatic functions, such as insulin secretion, has not been
studied yet. 
Insulin secretion is mainly triggered by the elevation of intra-
cellular Ca2, but it can be modulated by several cellular signals
such as protein kinases and phospholipases. Of these signals,
mammalian phospholipase D (PLD) is a membrane-bound
enzyme that hydrolyzes phosphatidyl choline (PC) to generate a
multifunctional lipid, phosphatidic acid (PA), in response to a vari-
ety of signals, including growth factors [17]. PA is an intracellular
lipid second messenger that is involved in multiple physiological
events. These findings suggest that agonist-induced PLD activa-
tion may play roles in multiple signalling events [18, 19]. To date,
two types of mammalian PLD, PLD1 and PLD2, have been cloned.
They share a sequence homology of around 50% and contain
similar regulatory domains. However, they show differences in
localization and regulatory protein interactions [20]. PLD activity
may be involved in various trafficking processes, particularly in
the regulation of exocytosis [18]. PLD1 and PLD2 regulate different
phases of exocytosis in mast cells by a two-step process [21]. In
addition, PA is an important mediator of insulin exocytosis [22].
However, the specific regulation of PLDs by secretagogues
remains unclear. Interestingly, PLD activity is inhibited in diabetic
animals [23]. Therefore, it is important to study how secreta-
gogues or receptor-mediated PLD activation is involved in 
insulin secretion. 
Here, we show that a brief exposure to EGF stimulates insulin
secretion in a glucose-independent manner via a Ca2 influx-
and PLD2-dependent mechanism. Furthermore, we show that
EGF is a novel secretagogue that lowers plasma glucose levels in
normal and diabetic mice, suggesting the potential for EGF treat-
ment in diabetes.
Materials and methods
Materials 
The enhanced chemiluminescence (ECL) kit was purchased from Amersham
Pharmacia Biotech (Buckinghamshire, United Kingdom); [3H]myristic acid
from Dupont NEN (Boston, MA, USA); Silica Gel 60 thin-layer chromatog-
raphy plates from MERCK (Darmstadt, Germany); Dulbecco’s modified
Eagle’s medium (DMEM), RPMI 1640 and LipofectAMINE from Invitrogen
(Carlsbad, CA, USA); Fetal calf serum from HyClone (Logan, UT, USA); EGF
from the Daewoong Pharmaceutical Company (Seoul, Republic of Korea);
AG1478 from CalBiochem (San Diego, CA, USA); Horseradish peroxidase-
conjugated goat anti-rabbit IgG and anti-mouse IgA, IgG and IgM from
Kirkegaard and Perry Laboratories, Inc. (Gaithersburg, MD, USA); and
Fluo-3 AM from Molecular Probes (Eugene, OR, USA). A polyclonal anti-
body (mSTP4) recognizing both PLD1 and PLD2 was produced as
described previously [24]. A PLD2-specific antibody was generated as
described previously [25]. All other chemicals were purchased from Sigma
(St. Louis, MO, USA). 
PLD constructs
The full-length cDNAs of rat PLD1 or human PLD2 were ligated into a
pcDNA 3.1 vector for transfection into cells. 
siRNA sequences
The siRNA of 21-mers corresponding to mouse PLD1 (nucleotides
1099–1119, AACACGUUAGCUAAGUGGUAU) or PLD2 sequences
(nucleotides 2539–2559, AACUCCAUCCAGGCUAUUCUG) were purchased
from Dharmacon Research Inc. (Lafayette, CO, USA). Results of a BLAST
search of all siRNA sequences revealed no significant homology to any
other sequences in the database.
[Ca2]i measurement
Changes in intracellular Ca2 levels were monitored using a Ca2-sensitive
dye under a confocal microscope. Cells were loaded with 2 µl Fluo-3 AM
for 40 min. at room temperature. After washing with Krebs-Ringer bicar-
bonate (KRB; 129 mM NaCl, 5 mM NaHCO3, 4.8 mM KCl, 1.2 mM KH2PO4,
1.0 mM CaCl2, 1.2 mM MgSO4, 2.7 mM glucose and 10 mM HEPES, pH 7.4)
buffer, the cells were further incubated for 15 min. in the absence of Fluo-
3 AM to de-esterify the dye. To exclude the possible effects of dye loading,
we normalized levels with saponin at the end of the experiments. To nor-
malize the data, we measured the residual fluorescence (Fo) at the end of
the experiment, and subtracted that from the fluorescence under experi-
mental conditions (F). Excitation of Fluo-3 AM was performed at 488 nm
by an argon laser, and the emission range was 515 nm. Images were cap-
tured on an inverted confocal microscope (Zeiss LSM 510 Meta,
Oberkochen, Germany) with a 20x objective lens.
PLD activity assay in cells
Cells grown in 6-well plates were washed twice with KRB, and were then
labelled with [3H]myristic acid for 4 hrs at 37°C in the KRB solution.
PLD activity was assayed by measuring the formation of phos-
phatidylbutanol (PBt) [26]. The intensities of PBt spots in the presence
of 0.4% 1-butanol were measured, and PLD activity was obtained by
subtracting the corresponding intensities of spots obtained in the
absence of 1-butanol.
Immunoblot analysis
Proteins were denatured by boiling for 5 min. at 95°C in Laemmli sample
buffer [27], separated by SDS-PAGE, and immunoblotted, as described
previously [26]. 
Cell culture
The mouse insulin-producing MIN6m9 cells provided by Dr. Susumu Seino
(Division of Cellular and Molecular Medicine, Kobe University Graduate
School of Medicine, Kobe, Japan) were used between passages 19 and 25,
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and were cultured in DMEM containing 25 mM glucose, 10 mM HEPES,
10% (v/v) foetal calf serum, 50 IU/ml penicillin and 50 µg/ml streptomycin
at 37°C in a humidified CO2-controlled (5%) incubator. MIN6 cells were
transfected using LipofectAMINE, as described previously [26] Transfection
efficiency is about 30–40% when using LipofectAMINE.
Preparation of pancreatic islets
Pancreatic islets were isolated from 7- to 8-week-old male BALB/c mice
(Hyochang Science, Republic of Korea), as described previously [28].
Isolated islets were transferred to a 12-well plate, with 10–15 islets per
well. We used the same number of islets in a same set of experiment. The
islets were maintained for up to 2 days in RPMI1640 medium containing
5 mM glucose and 10% foetal calf serum, and supplemented with 100 µg/ml
streptomycin and 100 U/ml penicillin.
Insulin secretion assay
Batches of 10–15 isolated islets or 1 x 106 cells/well grown in 12- or 
24-well plates were washed twice with KRB supplemented with 0.2%
bovine serum albumin (BSA), and were then incubated for 60 min. at
37°C in the KRB solution. We used the same number of islets in a same
set of experiment. At the end of incubation, the solutions were replaced
with fresh KRB containing test reagents and incubated for the desig-
nated time. The incubation medium was sampled and centrifuged 
to remove cells, and the supernatant was assayed for insulin levels with
a rat insulin radioimmunoassay (RIA) kit (Linco, St. Louis, MO, USA,
Cat. # RI-13K).
Measurement of plasma glucose and 
plasma insulin levels
Seven- to 8-week-old male ICR mice were purchased from Hyochang
Science (Seoul, Republic of Korea). C57BLKSJ-db/db mice were pur-
chased from SLC (Japan). After fasting for 6 hrs, ICR or C57BLKSJ-db/db
mice were intravenously injected with saline, EGF, insulin or glucose in the
tail vein and blood samples (0.1 ml) were subsequently collected.
Concentrations of plasma glucose were measured by the glucose oxidase
method with a portable glucose meter (Gluco-Dr, Republic of Korea).
Plasma was separated by centrifugation, and the plasma insulin assay was
performed using a RIA kit. Animal care was conducted in accordance with
the guidelines of our institution. 
Measurement of plasma EGF levels 
Seven- to 8-week-old male ICR mice were purchased from Hyochang
Science (Seoul, Republic of Korea). After fasting for 6 hrs, ICR mice
were orally injected with saline or glucose, and blood samples (0.1 ml)
were collected in EGTA coated tubes. Concentrations of plasma EGF
levels were measured by EGF ELISA kit (KOMA Biotech, Republic of
Korea). Animal care was conducted in accordance with the guidelines of
our institution.
Statistical analysis
Results are presented as mean  SE or mean  SD. The statistical signif-
icance of differences between means was assessed by Student’s t-test. P
0.05 was regarded as statistically significant.
Results
EGF stimulates insulin secretion in MIN6 cells
EGF is produced in the pancreas and has pancreatic effects, and its
circulating levels are altered in diabetes [6, 7]. To determine whether
EGF could stimulate insulin secretion, we treated mouse MIN6
insulinoma cells with EGF. EGF showed time- and dose-dependent
stimulation of insulin secretion from MIN6 cells, with kinetics more
rapid than glucose (Fig. 1A and B). EGFR is expressed throughout
the human foetal pancreas [12]. Moreover, the effect of EGF on the
release of insulin is quite rapid, and clearly detectable after 1 min.
Therefore, it is important to determine if EGF regulates insulin secre-
tion by acting directly through its own receptor. To address this
question, the effect of blocking of EGFR on the EGF-induced secre-
tion of insulin was examined. The EGFR blocker (AG1478) com-
pletely inhibited the EGF-induced insulin secretion (Fig. 1C).
Therefore, EGF induces insulin secretion through its own receptor.
In order to exclude the possible cross-talk between EGF and
glucagon-like peptide-1 (Glp-1) signalling, the effect of blocking of
the Glp-1 receptor on the EGF-induced secretion of insulin was
examined. The Glp-1 receptor blocker (EXENDIN fragment 9–39)
had no effect on the EGF-induced insulin secretion in MIN6 cells
(Supplement Fig. 1). Therefore, EGF induces insulin secretion
through its own receptor and not through Glp-1 cross-talk. To deter-
mine whether insulin secretion by EGF was additive by glucose
treatment, we tested the effect of a high level (11 mM) of glucose
on EGF-induced insulin secretion. EGF increased insulin levels at a
basal concentration of glucose (2.7 mM), and also additively
increased glucose-induced insulin release at high (11 mM) glucose
levels (Fig. 1D). Taken together, these data suggest that EGF, like
glucose, is an initiator of insulin secretion in pancreatic  cells, and
also indicate that the effect of EGF on insulin secretion is glucose-
independent.
EGF-induced insulin secretion is dependent 
on Ca21 influx in MIN6 cells
Insulin secretion requires increases in intracellular Ca2 con-
centrations ([Ca2]i) [2]. Figure 2A demonstrated that EGF
stimulated an extra-cellular Ca2 influx, which could be reduced
by EGTA treatment. To determine the effect of Ca2 influx on
EGF-induced insulin secretion, we treated cells with either EGTA to
block extra-cellular Ca2 influx or 1,2-Bis(2-aminophenoxy) ethane
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N,N,N',N' -tetra-acetic acid tetrakis(acet-oxymethyl ester)
(BAPTA/AM) to block both extra-cellular Ca2 influx and intracellu-
lar Ca2 release. EGF-induced insulin secretion from MIN6 cells
was reduced by Ca2 chelators (Fig. 2B). The same results were
also observed in RINm5F cells (data not shown). It would also be
worthwhile to determine if the EGF effect acts on the L-type Ca2
channels. This was confirmed by examining the effect of nifedipine,
L-type Ca2 channel inhibitor, rather than a non-selective chelator
in the same experiment. The results showed that nifedipine blocked
the EGF-dependent insulin secretion in a similar manner to that
observed with the EGTA treatment (Fig. 2C). Taken together, these
results suggest that the Ca2 influx is neces sary for EGF-induced
insulin secretion, particularly through L-type Ca2 channels.
PLD2 mediates EGF-dependent insulin secretion
in MIN6 cells
Previous reports have suggested that PLD is an important mole-
cule that mediates various exocytosis [18, 21, 22]. Furthermore,
EGF is a strong agonist of PLD in various cells [29–31]. To inves-
tigate this, we first tested the PLD activity in MIN6 cells. PLD was
rapidly activated (within 2 min.) by EGF stimulation (Fig. 3A).
EGF-dependent insulin secretion was inhibited by treatment with
1-butanol, a PLD inhibitor, but not by t-butanol treatment as a
control (Fig. 3B). These results suggest that PLD activity is nec-
essary for EGF-induced insulin secretion. The same results were
also observed in RINm5F cells (data not shown).
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Fig. 1 EGF rapidly and glucose-independ-
ently stimulates insulin secretion in MIN6
cells. (A–D) The MIN6 cells were plated
onto 24-well plates and grown for 24 hrs.
The cells were washed twice with KRB sup-
plemented with 0.2% BSA, and were then
incubated for 60 min. at 37°C in the KRB
solution. (A) At the end of incubation, the
solutions were replaced with fresh KRB
containing none (NT), 15 nM EGF or 11
mM glucose, and were incubated for 0, 1,
2, 5 or 10 min. The incubation medium
was sampled for measuring insulin levels.
*P  0.05 compared with not-treated (NT)
cells. (B) At the end of incubation, the solu-
tions were replaced with fresh KRB con-
taining 0, 1.5, 15 or 150 nM of EGF, and
were incubated for 1 min. The incubation
medium was sampled for measuring
insulin levels. *P  0.05 compared with
not-treated cells. (C) At the end of incuba-
tion, the solutions were replaced with fresh
KRB containing none (untreated) or 10 µM
AG1478 and were incubated for 30 min.,
and were then treated with 15 nM EGF for 0
or 1 min. The incubation medium was
sampled for measuring insulin levels. *P 
0.05 compared with EGF-treated cells. (D)
At the end of incubation, the solutions were
replaced with fresh KRB containing 0, 15 or
30 nM of EGF in the presence of 2.7 or 11
mM glucose, and were incubated for 5
min. The incubation medium was sampled
for measuring insulin levels. * or **P 
0.05 compared with 2.7 or 11 mM glu-
cose-treated cells. (A–D) The data shown
are the mean  S.D. from two independent
assays performed in duplicate.
Supplement Fig. 1 EGF-induced insulin secretion is not affected by Glp-1 receptor inhibitor. The MIN6 cells were plated onto 24-well plates and grown
for 24 hrs. The cells were washed twice with KRB supplemented with 0.2% BSA, and were then incubated for 60 min. at 37°C in the KRB solution. At
the end of incubation, the solutions were replaced with fresh KRB containing none (untreated) or 100 nM EXENDIN fragment [9–39] and were incu-
bated for 30 min., and were then treated with 15 nM EGF for 0 or 1 min. The incubation medium was sampled for measuring insulin levels. The data
shown are the mean  S.D. from two independent assays performed in duplicate.
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To identify the PLD isozyme responsible for stimulating insulin
secretion, we examined the effects of the over-expression and
silencing of PLD isozymes. We transfected MIN6 cells with an
empty vector, PLD1 or PLD2, and stimulated them with EGF. PLD1
mediated glucose-dependent insulin secretion, as shown previ-
ously (data not shown) [32]. In contrast, PLD2 exclusively medi-
ated EGF-dependent insulin secretion, and over-expression of
PLD1 showed a limited effect (Fig. 3C). Furthermore, silencing 
of PLD2, but not PLD1, abolished EGF-induced insulin secretion
(Fig. 3E). The same results were also observed in RINm5F cells
(data not shown). Finally, EGF-dependent PLD activity, as meas-
ured with PBt formation, was modulated exclusively by PLD2 over-
expression or silencing (Fig. 3D and F), which suggests that PLD2
is required for EGF-stimulated insulin secretion in these cells.
PLD activity is dependent on Ca2 influx 
in MIN6 cells
Because both a Ca2 influx and PLD activity are required for EGF-
dependent insulin secretion, we analysed the relationship between
the two phenomena by testing the effect of the Ca2 influx on PLD
activity and the effect of PLD activity on the Ca2 influx. Blocking
Ca2 influx by using EGTA or BAPTA/AM inhibited most of the PLD
activity (Fig. 4A), which correlated with EGF-dependent insulin
secretion (Fig. 2B). However, inhibiting PLD activity by silencing
PLD isozymes, which we confirmed through successful silencing
of PLDs by Western blotting, had little effect on the EGF-dependent
Ca2 influx (Fig. 4B), which suggest that the Ca2 influx is
upstream of PLD activation in EGF-dependent insulin secretion.
EGF-stimulated insulin secretion in mouse 
pancreatic islets requires Ca2 influx 
and PLD activity
To confirm the physiological significance of EGF, Ca2 and PLD on
insulin secretion, we prepared primary cultures of mouse islets.
As expected, EGF rapidly increased insulin secretion (Fig. 5A) with
a 1-min. treatment. Inhibiting the Ca2 influx or PLD activity com-
pletely blocked the EGF-induced insulin secretion (Fig. 5B and C),
thus indicating that EGF-stimulated insulin secretion in mouse
pancreatic islets requires a Ca2 influx and PLD.
EGF lowers plasma glucose and increases plasma
insulin levels
To confirm our in vitro findings that EGF could stimulate the
release of insulin, we characterized the EGF-mediated responses
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Fig. 2 Ca2 influx mediates the EGF-triggered insulin secretion in MIN6 cells. (A–C) The MIN6 cells were plated onto glass dishes or 
24-well plates and grown for 24 hrs. The cells were washed twice with KRB supplemented with 0.2% BSA, and were then incubated for
60 min. at 37°C in the KRB solution. (A) At the end of incubation, the solutions were replaced with fresh KRB containing Fluo-3 AM 
dissolved (1 mg/ml) in DMSO, and were incubated for 1 hr. At the end of incubation, cells were incubated with none (untreated) or 1 mM
EGTA for 30 min., and were then treated with 15 nM EGF. Images were captured on an inverted confocal microscope with a 20( objec-
tive lens. The data shown are the mean  S.E., n  7. (B) At the end of incubation, the solutions were replaced with fresh KRB contain-
ing none (untreated), 1 mM EGTA or 5 µM BAPTA/AM and were incubated for 30 min., and were then treated with 15 nM EGF for 0 or 
1 min. The incubation medium was sampled for measuring insulin levels. *P  0.05 compared with EGF-treated cells. (C) At the end of
incubation, the solutions were replaced with fresh KRB containing none (untreated) or 10 µM nifedipine and were incubated for 30 min.,
and were then treated with 15 nM EGF for 0 or 1 min. The incubation medium was sampled for measuring insulin levels. *P  0.05 
compared with EGF-treated cells. (B–C) The data shown are the mean  S.D. from two independent assays performed in duplicate.
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Fig. 3 PLD2 is specifically involved in
the EGF-dependent insulin secretion. (A)
The MIN6 cells were plated onto 6-well
plates and grown for 24 hrs. The cells
were washed twice with KRB, and were
then incubated for 4 hrs at 37°C in the
KRB solution in the presence of
[3H]myristic acid. At the end of incuba-
tion, 15 nM EGF stimulation was per-
formed for the indicated amount of time.
The intensities of PBt spots were meas-
ured after 0-, 1-, 2-, 5- or 10-min. accu-
mulation in the presence of 1-butanol
and EGF. (B) The MIN6 cells were plated
onto 24-well plates and grown for 24
hrs. The cells were washed twice with
KRB supplemented with 0.2% BSA, and
were then incubated for 60 min. at 37°C
in the KRB solution. At the end of incu-
bation, the solutions were replaced with
fresh KRB containing 0.4% t-butanol or
1-butanol and were incubated for 10 min.,
and were then treated with 15 nM EGF
for 0 or 1 min. The incubation medium
was sampled for measuring insulin 
levels. *P  0.05 compared with EGF-
treated cells. (C–F) The MIN6 cells were
plated onto 24-well plates (for measur-
ing insulin levels) or 6-well plates (for
measuring PLD activity) and transfected
with the indicated plasmids (vector,
PLD1, or PLD2 in Fig. 3C and D) or
siRNAs (control (luciferase), mouse
PLD1 or mouse PLD2 in Fig. 3E and F)
grown for 24 or 72 hrs. The efficiencies
of transfection were approximately
30–40%. For measuring insulin secre-
tion (Fig. 3C and E), the cells were
washed twice with KRB supplemented
with 0.2% BSA, and were then incubated
for 60 min. at 37°C in the KRB solution.
At the end of incubation, the solutions
were replaced with fresh KRB containing
15 nM EGF, and were incubated for 0 or
1 min. The incubation medium was sam-
pled for measuring insulin levels. *P 
0.05 compared with EGF-treated cells.
For measuring PLD activity (Fig. 3D and
F), the cells were washed twice with
KRB, and were then incubated for 4 hrs
at 37°C in the KRB solution in the pres-
ence of [3H]myristic acid. At the end of
incubation, 15 nM EGF stimulation was
performed for 0 or 1 min. The intensities
of PBt spots were measured after 1 min.
of accumulation in the presence of 
1-butanol and EGF. *P  0.05 compared 
with EGF-treated cells. Cells were lysed with KRB containing 0.1% Triton X-100 and subjected to SDS-PAGE, and were then immunoblot-
ted using anti-PLDs antibody (inner boxes of Fig. 3C and D) and PLD1 (inner boxes of Fig. 3E and F), PLD2-specific antibody (inner boxes
of Fig. 3E and F) or actin antibody (inner boxes of Fig. 3C–F). (A–F) The data shown are the mean  S.D. from two independent assays per-
formed in duplicate.
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of mouse plasma glucose and insulin levels in normal and obese
db/db mice by injecting EGF intravenously. In preliminary experi-
ments, EGF (50 µg/kg) achieved a saturated plasma glucose-low-
ering effect 10 min. after intravenous injection into 7- to 8-week-
old male ICR mice (data not shown). This glucose-lowering effect
of EGF (50 µg/kg) had a similar potency to insulin and was dose-
dependent (Fig. 6A). Moreover, EGF increased plasma insulin lev-
els (Fig. 6B), which suggests that this glucose-lowering effect is
due to changes in plasma insulin levels. The kinetics of insulin
secretion and changes in glucose were correlated. EGF also
reduced plasma glucose in obese db/db mice and increased
plasma insulin levels (Fig. 6C and D). Taken together, we conclude
that EGF has the ability to stimulate insulin secretion and lower
plasma glucose in normal and diabetic mice models. 
Glucose increases plasma EGF levels
EGF can regulate glucose homeostasis. Therefore, it is possible
that the EGF levels in the body can be regulated by the feeding
condition. Glucose was injected intravenously into 7- to 8-week-old
male ICR mice and the plasma EGF levels were measured (Fig. 7).
Twenty minutes after the glucose injection, the plasma EGF levels
were elevated. Because glucose stimulates EGF and insulin secretion,
it is possible that if insulin level is increased and thereby glucose
level is reduced, the opposite effect will be observed on EGF con-
centration. To test this hypothesis, insulin was injected intra-
venously 20 min. after the intravenous glucose injection. The
results were compared with those from the intravenous saline
injection. As a result, the insulin injection significantly attenuated
the increase in EGF elevation caused by glucose (Fig. 7). In addi-
tion, an oral injection of glucose had the same effect of plasma
EGF elevation (data not shown). This suggests that the physiolog-
ical concentration of EGF can be altered by the feeding conditions,
and secreted EGF finally regulates insulin secretion. Although the
exact source of secreted EGF is not known, it can be assumed that
this increase in plasma EGF induced by the physiological glucose
concentration can rapidly mediate the regulation of pancreatic
insulin secretion.
Discussion
Insulin synthesis, processing and secretory pathways are highly
regulated and dynamic processes. Many factors, including 
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Fig. 4 Ca2 influx is critical for the EGF-induced PLD activation. (A) The MIN6 cells were plated onto 6-well plates and grown for 24 hrs. The cells
were washed twice with KRB, and were then incubated for 4 hrs at 37°C in the KRB solution in the presence of [3H] myristic acid. At the end of incu-
bation, the solutions were replaced with fresh KRB containing none (untreated), 1 mM EGTA or 5 µM BAPTA/AM and were incubated for 30 min., and
were then treated with 15 nM EGF for 0 or 1 min. The intensities of PBt spots were measured after 1 min. of accumulation in the presence of 1-butanol.
The data shown are the mean  S.D. from two independent assays performed in duplicate. *P  0.05 compared with EGF-treated cells. (B) The MIN6
cells were plated onto glass dishes and transfected with siRNAs (control [luciferase], mouse PLD1 or mouse PLD2), and were then grown for 24 hrs.
The cells were washed twice with KRB supplemented with 0.2% BSA, and were then incubated for 60 min. at 37°C in the KRB solution. At the end of
incubation, the solutions were replaced with fresh KRB containing Fluo-3 AM dissolved (1 mg/ml) in DMSO and were incubated for 1 hr. At the end
of incubation, cells were treated with 15 nM EGF. Images were captured on an inverted confocal microscope with a 20x objective lens. The data shown
are the mean  S.E. of the peak time, n  7. Cells were lysed with KRB containing 0.1% Triton X-100 and subjected to SDS-PAGE, and were then
immunoblotted using anti-PLDs antibody (inner box of Fig. 4B), PLD2-specific antibody (inner box of Fig. 4B) or actin antibody (inner box of Fig. 4B).
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nutrients, neurotransmitters and hormones, affect these processes
[1, 2]. In this study, for the first time we show that EGF is a novel
secretagogue that regulates plasma glucose levels, and determine
the mechanism of EGF-induced insulin secretion.
Type 2 diabetes mellitus is characterized by both insulin resist-
ance and impaired insulin secretion. The control of insulin secre-
tion is primarily regulated by glucose itself, but also involves an
array of metabolic, neural, hormonal and sometimes pharmaco-
logic factors [1, 33]. Initiators can increase insulin secretion in the
absence of other stimulation, but potentiators require the pres-
ence of an initiator, usually glucose [1]. Many growth factors are
also secreted from the pancreas or affect the pancreas, and their
levels are often changed in diabetes [34–36]. However, few stud-
ies have been conducted to assess about the role of growth fac-
tors in regulating plasma glucose or as insulin secretion initiators.
EGF requires only brief exposure (1 min.) to stimulate insulin
secretion (Fig. 1A), and increases Ca2 levels when treated alone
(Fig. 2A), which indicates that it can function as an initiator.
Furthermore, EGF additively stimulates glucose-dependent insulin
secretion (Fig. 1D), which means that the EGF effect is glucose-
independent. Insulin secretion by glucose has a biphasic pattern,
with a peak around 5 min., a nadir at 10 min. and a slowly increas-
ing time-course thereafter. This first phase is key for the insulin-
dependent processes that ensure glucose homeostasis [3]. The
time-course of EGF receptor-mediated insulin secretion is similar
to neurotransmitter release in neuronal cells, and is more rapid
than the first phase of glucose-dependent insulin secretion from
pancreatic  cells. The EGF-induced release of insulin required a
rapid Ca2 influx compared with glucose, which requires 3–4 min.
for Ca2 influx, mainly due to the time for glucose metabolism and
a delayed change of the ATP/ADP ratio (data not shown). Insulin
secretion can sometimes be regulated through classical signalling
cascades involving transmembrane receptors, heterotrimeric 
G-proteins and second messengers [36–38]. Therefore, EGF
receptor-mediated regulation of insulin secretion is not unreason-
able. Here, we defined a new role for EGF as an initiator of insulin
secretion, both in vitro and in vivo, thus indicating the therapeutic
potential of EGF in diabetes.
PLD is activated by EGF stimulation, and this activation is a
very rapid process compared to those of other PLD-regulating
molecules such as glucose [30, 32]. The mechanism underlying
EGF-mediated activation of PLD remains controversial [29–31,
39]. Among the potential mechanisms, EGF-dependent increases
in Ca2 activate protein kinase C (PKC) and lead to PLD activation
[40]. Another report suggested that a Ca2 influx is associated
with the activation of PLD, and that PKC is involved in this process
[41]. However, there have been limited studies related to the Ca2-
mediated PLD activation of specific isozymes. In the present
study, we identified PLD2 as a Ca2-dependent isozyme in the
pancreatic  cells using EGF treatment (Fig. 3C–F). Although
PLD1 and 2 share a sequence homology of around 50% and con-
tain similar regulatory domains [20], they show differences in
localization and regulatory protein interactions [39, 42]. A previ-
ous report suggested that PLD1 and PLD2 regulate different
© 2008 The Authors
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Fig. 5 Insulin secretion is increased by EGF in mouse pancreatic islets through Ca2 influx and PLD activity. (A–C) Mouse pancreatic islets were
plated onto 12-well plates and grown for 24 hrs. The islets were washed twice with KRB supplemented with 0.2% BSA, and were then incubated for
60 min. at 37°C in the KRB solution. (A) At the end of incubation, the solutions were replaced with fresh KRB and were incubated for 1 or 5 min.
with none (NT), 15 nM EGF or 11 mM glucose. The incubation medium was sampled for measuring insulin levels. * or **, P  0.05 compared with
1- or 5-min.-treated islets. (B) At the end of incubation, the solutions were replaced with fresh KRB containing none (untreated), 1 mM EGTA or 5
µM BAPTA/AM and were incubated for 30 min., and were then treated with 15 nM EGF for 0 or 1 min. The incubation medium was sampled for meas-
uring insulin levels. *P  0.05 compared with EGF-treated islets. (C) At the end of incubation, the solutions were replaced with fresh KRB containing 0.4%
of t-butanol and 1-butanol and were incubated for 10 min., and were then treated with 15 nM EGF for 0 or 1 min. The incubation medium was sampled for
measuring insulin levels. *P  0.05 compared with EGF-treated islets. (A–C) The data shown are the mean  S.D. from two independent assays performed
in duplicate.
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phases of exocytosis in mast cells via a two-step process [21]:
translocation of granules to the cell periphery, regulated by gran-
ule-associated PLD1, and a Ca2-dependent fusion of granules
with the plasma membrane, regulated by plasma mem-
brane–associated PLD2. Differently from the previous report sug-
gesting PLD1 as a mediator of glucose-stimulated insulin secre-
tion [32], in our hands, EGF stimulation required the activation of
PLD2. The specific activations of PLD1 by glucose and of PLD2 by
EGF have different kinetics, and their mechanisms require further
clarification. We detected PLD2 in MIN6 cells, both by Western
blotting using a PLD2-specific antibody (Fig. 3C–F) and by RT-
PCR (data not shown). Furthermore, we used over-expression and
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Fig. 6 EGF lowers plasma glucose and
increases plasma insulin levels. (A) Seven- to
8-week-old male ICR mice (10 mice/group)
received intravenous injections of saline
(0.9% NaCl in double-distilled water), insulin
(0.06 U/kg) or EGF (18.5 or 50 µg/kg), and
plasma glucose levels were subsequently
measured. † (insulin), * (EGF 50 µg/kg) or 
** (EGF 18.5 µg/kg), P  0.05 compared with
saline-treated mice in the indicated amount of
time. (B) Seven- to 8-week-old male ICR mice
(10 mice/group) received intravenous injec-
tions of saline, glucose (0.5 g/kg) or EGF
(18.5 or 50 µg/kg), and plasma insulin levels
were subsequently measured. ‡ (glucose), 
* (EGF 50 µg/kg) or ** (EGF 18.5 µg/kg), 
P  0.05 compared with saline-treated mice
in the indicated amount of time. (C) Obese
C57BLKSJ-db/db mice (six mice per group)
received intravenous injections of saline
(0.9% NaCl in double-distilled water), insulin
(0.06 U/kg) or EGF (50 µg/kg), and plasma
glucose levels were subsequently measured.
† (insulin) or * (EGF 50 µg/kg), P  0.05
compared with saline-treated mice in the indi-
cated amount of time. (D) Obese C57BLKSJ-
db/db mice (six mice per group) received
intravenous injections of saline, glucose 
(0.5 g/kg) or EGF (50 µg/kg), and plasma
insulin levels were subsequently measured.
Plasma insulin levels before and 10 min. after
injection were compared. ‡ (glucose) or 
* (EGF 50 µg/kg), P  0.05 compared with
saline-treated mice in the indicated amount of
time. All animals had free access to water.
Animal care was conducted in accordance
with the guidelines of our institution. (A–D)
The data shown are mean  S.E.
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silencing strategies to determine that PLD2, not PLD1, mediated
EGF-dependent insulin secretion (Fig. 3C and E). These results
suggest that glucose stimulates insulin secretion via PLD1 with a
relatively late time course, whereas EGF activates plasma mem-
brane–localized PLD2, leading to rapid fusion of pre-docked insulin
granules with the plasma membrane. Our work supports the
notion that PLD1 and PLD2 mediate different pathways for regu-
lating insulin secretion. Since PLDs are important molecules in
exocytotic processes, the investigation of PLDs will provide signif-
icant insight into the regulatory mechanisms of insulin secretion. 
Metabolism of glucose results in the closure of ATP-sensitive
K channels, and the subsequent plasma membrane depolariza-
tion opens voltage-sensitive Ca2 channels [43]. The resultant
rise in the cytoplasmic free Ca2 concentration is both necessary
and sufficient for triggering an initial phase of insulin release that
is mediated by the fusion of pre-docked insulin granules with the
plasma membrane [38]. Our results show that an EGF-stimulated
Ca2 influx mediates insulin secretion, especially through L-type
Ca2 channels (Fig. 2B and C). EGF was reported to regulate
store-operated Ca2 channel activation, as well as Ca2 release
from stores. Previous studies suggest that proliferative responses
to EGF are dependent on the cellular influx of Ca2 through Ca2-
selective channels [44, 45]. In the present work, we determined
that EGF-stimulated insulin secretion required both Ca2 influx
and PLD activity (Figs. 2B and 3B). Our findings (Fig. 4) suggest
that the Ca2 influx is an upstream signal for PLD activity. A pre-
vious report has indicated that secretory stimuli activate PLD
activity in pancreatic  cells [32]: treatment with channel blockers
profoundly decreased insulin secretion from MIN6 cells, as well as
the cellular PLD activity, in the presence of glucose. Accordingly,
our results strongly indicate a close relationship between a secre-
tagogue-induced Ca2 influx and PLD activity in insulin secretion
by pancreatic  cells. 
EGF regulates pancreatic function and is produced in the pan-
creas and pancreatic juice [6, 46]. EGFR is expressed throughout
the human foetal pancreas, and mice lacking EGFR showed abnor-
mal formation of pancreatic islets [12]. Some members of the EGF
family play a role in the development of the pancreas [11]. EGF
regulates the insulin content of rat pancreatic  cells as well as
their regeneration [13–15]. Furthermore, EGF deficiency is associ-
ated with diabetes mellitus; in diabetic animals, EGF or EGFR lev-
els are decreased in various organs or fluids, such as the liver, the
submandibular gland, plasma and milk [7, 16, 47, 48].
Interestingly, levels of these proteins often recover after insulin
curative treatment [48], and EGF and insulin act synergistically
during diabetic healing [49]. A recent report suggested that EGF
can regulate glucose homeostasis [50]. They focused on the role
of EGF in regulating the plasma glucagon levels depending on the
presence of glucose, and observed this effect using an animal
model. Furthermore, combination therapy with EGF and gastrin
induced -cell regeneration in rodents with chemically induced
diabetes [15]. Therefore, this study focused on the plasma insulin
levels based on the results from insulinoma cell lines and islets,
and determined the mechanism of EGF-dependent insulin secre-
tion. Consistent with our in vitro findings from MIN6 (Fig. 1),
RINm5F (data not shown) cell line and mouse pancreatic islets 
(Fig. 5), which indicated that EGF could stimulate the release of
insulin, we found that EGF increased plasma insulin levels and
decreased plasma glucose levels in normal and even in diabetic
mice (Fig. 6). Furthermore, we observed that physiological EGF
levels were increased by a glucose injection and decreased after a
sequential insulin injection (Fig. 7). While the effect of insulin to
reduce the EGF levels after the glucose injection may indeed be
secondary to the reduction of blood glucose, it is also possible
that insulin could suppress EGF through a direct mechanism.
From these results, we speculate that physiological EGF rapidly
increases insulin secretion, and this process might be important
in short-term regulation of plasma glucose levels. Although the
exact source of secreted EGF is unknown, it can be assumed that
this increase in plasma EGF induced by the physiological glucose
concentration can rapidly mediate pancreatic insulin secretion.
Further studies will be needed to determine which pancreatic cells
secrete EGF and how this secretion is regulated. It is likely that
EGF-dependent insulin secretion plays a similar function to that of
glucose on glucose homeostasis in our body. Reducing the
endogenous level of EGF using knock-down, antibody, or aptamer
would indicate the physiological function of EGF on glucose and
insulin homeostasis. Taken together, our observations on the role
of EGF on insulin secretion and -cell regeneration may contribute
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Fig. 7 Glucose increases plasma EGF levels. Seven- to 8-week-old
male ICR mice (seven mice per group) received intravenous injections
of saline or glucose (2 g/kg) for a first injection (0 min.), and saline or
insulin (0.06 U/kg) for a second injection (20 min.). As indicated, group
and plasma EGF and glucose levels were subsequently measured. The
data shown are the mean  S.E., * or **P  0.05 compared with
saline-treated mice in the indicated amount of time. All animals had
free access to water. Animal care was conducted in accordance with
the guidelines of our institution.
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to a better understanding of the pathophysiology of diabetes mel-
litus, in which serum EGF levels are diminished. Furthermore, the
effect of EGF in diabetic mice indicates the potential usefulness of
EGF as a potential treatment of diabetes.
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